Affimed N.V. Price & Performance (AFMD)

Affimed N.V. has been notified by Nasdaq that its stock price has closed below the $1 minimum for 30 consecutive business days, putting its listing at risk. The company now has 180 days to regain compliance or face potential transfer to a lower-tier market, extending its timeline but not guaranteeing continued listing.12

Despite a recent dip below Nasdaq’s minimum bid threshold, Affimed continues to receive robust analyst support. The average price target is significantly higher than current levels, with consensus ratings remaining at 'Strong Buy.' However, technical indicators and short-term trends suggest ongoing volatility and caution for investors.34

Affimed N.V. is expected to post a quarterly loss of 81 cents per share but show a substantial revenue increase compared to last year, according to analyst estimates. The company’s clinical progress and analyst price targets remain optimistic, yet near-term financial performance is still under pressure.56